- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00338650
Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)
November 28, 2007 updated by: Abbott
A Multi-Center, Open-Label Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Patients With Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab
The primary objective of this study is to make adalimumab available to patients suffering from moderately to severely active Crohn's Disease who have failed to respond to, lost response to, or are intolerant to infliximab, and to evaluate safety
Study Overview
Study Type
Interventional
Enrollment
1000
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35209
-
-
Arkansas
-
Jonesboro, Arkansas, United States, 72401
-
Little Rock, Arkansas, United States, 72205
-
-
California
-
Roseville, California, United States, 95661
-
San Francisco, California, United States, 94115
-
-
Colorado
-
Englewood, Colorado, United States, 80113
-
Wheat Ridge, Colorado, United States, 80033
-
-
Connecticut
-
Bridgeport, Connecticut, United States, 06606
-
Hamden, Connecticut, United States, 06518
-
-
Florida
-
Clearwater, Florida, United States, 33765
-
Gainesville, Florida, United States, 32607
-
Gainesville, Florida, United States, 32610
-
Hollywood, Florida, United States, 33021
-
Jacksonville, Florida, United States, 32256
-
Jacksonville, Florida, United States, 32224
-
Miami, Florida, United States, 33173
-
North Miami Beach, Florida, United States, 33162
-
Winter Park, Florida, United States, 32789
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
-
Atlanta, Georgia, United States, 30308
-
Atlanta, Georgia, United States, 30309
-
Conyers, Georgia, United States, 30012
-
Marietta, Georgia, United States, 30060
-
Savannah, Georgia, United States, 31405
-
-
Illinois
-
Arlington Heights, Illinois, United States, 60005
-
Moline, Illinois, United States, 61265
-
Rockford, Illinois, United States, 61107
-
-
Indiana
-
Columbus, Indiana, United States, 47201
-
Indianapolis, Indiana, United States, 46237
-
Indianapolis, Indiana, United States, 46202-5250
-
-
Iowa
-
Clive, Iowa, United States, 50325
-
Davenport, Iowa, United States, 52807
-
-
Kansas
-
Overland Park, Kansas, United States, 66212
-
Topeka, Kansas, United States, 66606
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
-
-
Maryland
-
Annapolis, Maryland, United States, 21401
-
Chevy Chase, Maryland, United States, 20815
-
Lutherville, Maryland, United States, 21093
-
Silver Spring, Maryland, United States, 20901
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
-
Boston, Massachusetts, United States, 02118
-
Burlington, Massachusetts, United States, 01805
-
-
Michigan
-
Troy, Michigan, United States, 48098
-
-
Minnesota
-
Plymouth, Minnesota, United States, 55446
-
-
Mississippi
-
Picayune, Mississippi, United States, 39466
-
-
Missouri
-
Kansas City, Missouri, United States, 64131
-
Mexico, Missouri, United States, 65265-3726
-
St. Louis, Missouri, United States, 63128
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
-
-
New Jersey
-
Egg Harbor Township, New Jersey, United States, 08234
-
Glen Ridge, New Jersey, United States, 07028
-
Manalapan, New Jersey, United States, 07726
-
-
New York
-
Great Neck, New York, United States, 11021
-
Lake Success, New York, United States, 11042
-
New York, New York, United States, 10021
-
New York, New York, United States, 10022
-
New York, New York, United States, 10028
-
New York, New York, United States, 10128
-
Rochester, New York, United States, 14607
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28207
-
Charlotte, North Carolina, United States, 28211
-
Jacksonville, North Carolina, United States, 28546
-
Rocky Mount, North Carolina, United States, 27804
-
Wilmington, North Carolina, United States, 28401
-
Wilmington, North Carolina, United States, 28403
-
-
Ohio
-
Beachwood, Ohio, United States, 44122
-
Cincinnati, Ohio, United States, 45220
-
Cincinnati, Ohio, United States, 45242
-
Cincinnati, Ohio, United States, 45219
-
Cleveland, Ohio, United States, 44195
-
Warren, Ohio, United States, 44484
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74104
-
Tulsa, Oklahoma, United States, 74135
-
-
Oregon
-
Portland, Oregon, United States, 97225
-
Portland, Oregon, United States, 97220
-
-
Pennsylvania
-
Beaver Falls, Pennsylvania, United States, 15010
-
Duncansville, Pennsylvania, United States, 16635
-
Philadelphia, Pennsylvania, United States, 19107
-
Pittsburgh, Pennsylvania, United States, 15232
-
Pittsburgh, Pennsylvania, United States, 15224
-
Pittsburgh, Pennsylvania, United States, 15243
-
Sayre, Pennsylvania, United States, 18840
-
-
South Carolina
-
Columbia, South Carolina, United States, 29204
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37404
-
Chattanooga, Tennessee, United States, 37403
-
Germantown, Tennessee, United States, 38138
-
-
Texas
-
Austin, Texas, United States, 78745
-
-
Utah
-
South Ogden, Utah, United States, 84405
-
-
Virginia
-
Norfolk, Virginia, United States, 23502
-
-
Washington
-
Bellevue, Washington, United States, 98004
-
Seattle, Washington, United States, 98101
-
Spokane, Washington, United States, 99204
-
Vancouver, Washington, United States, 98664
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
-
Milwaukee, Wisconsin, United States, 53233
-
Milwaukee, Wisconsin, United States, 53215
-
Monroe, Wisconsin, United States, 53566
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient diagnosed with moderate to severe Crohn's Disease.
- Failed prior infliximab therapy.
- Patient is judged to be in generally good health as determined by the principal investigator.
Exclusion Criteria:
- Previous treatment with adalimumab.
- Patient considered by the investigator, for any reason, to be an unsuitable candidate
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
AEs, laboratory data, physical examinations and vital signs
|
Secondary Outcome Measures
Outcome Measure |
|---|
|
Efficacy variables will be assessed from Outcomes Questionnaires
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2006
Study Completion (Actual)
May 1, 2007
Study Registration Dates
First Submitted
June 19, 2006
First Submitted That Met QC Criteria
June 19, 2006
First Posted (Estimate)
June 20, 2006
Study Record Updates
Last Update Posted (Estimate)
November 29, 2007
Last Update Submitted That Met QC Criteria
November 28, 2007
Last Verified
November 1, 2007
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- M06-808
- CHOICE
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.